Keytruda and Padcev generated promising topline results for those with muscle-invasive bladder cancer who are ineligible for ...

A new bladder cancer device called TAR-200 kept most patients cancer-free and surgery-free in a trial, with few side effects ...

Programmed death-1 (PD-1) inhibition with pembrolizumab led to durable remission in 31.3% of patients with early acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapse after ...

During a live event, Nataliya Mar, MD, discussed systemic therapies such as lenvatinib/pembrolizumab in advanced renal cell ...

In August 2025, Seagen announced a studies how well tucatinib works for solid tumors that make either more HER2 or a ...